Ok, so the first post of the series covered Trisomies because when you talk about cytogenetics or HR-MM, you might as well call it the the good, the bad, and the ugly and I wanted to start out with the good. Yep, it's all downhill from here, so get your skis or head out for Insano.
Next up are translocations.
I am the sort of person who likes to see the big picture first before I get bogged down in the details, as it helps to understand the ove
This is a long post and the information is complex.
However, I can assure you it is well worth your time even if it may take awhile to digest (i.e. read multiple times). I can't tell you how many times I had to read & re-read science information to become 'educated' lol. I did it. You can too. My tip, just read a bit. Digest it. Then come back and read some more. It is well worth it as it matters to be an informed patient. Especial
“The current definition of multiple myeloma that requires end-organ damage is outdated. We are now saying there are other factors besides end organ damage that can be used to identify patients who need therapy.”
Earlier Intervention is Key
In a News& Views write up from Nature Reviews, Dr. Rajkumar, G. Merlini,& J.F. SanMiguel discuss redefining myeloma and in particular redefining treatment guidelines for SMM.
The 18th Congress of the European Hematology Association (EHA) has convened this weekend in Stockholm, Sweden. The EHA membership includes over 100 countries and myeloma experts from across the globe have submitted abstracts of clinical significance for discussion and presentation. Many of the abstracts were presented at ASCO which just ended. There are a few that I believe are worth hig
Alright, I have selected another difficult topic to post about. While attempting to write about and explain immune checkpoints I decided that music and orchestras make a good metaphor for the immune system. Beautiful music relies on the pitch & sound of different instruments to be coordinated and our immune system also relies on checkpoint molecules (instruments) knowing when it is their turn to play (the right notes) and for how lo
Well, one of the world's distinguished leaders in myeloma, Gareth Morgan is at it again, bringing us significant clinical news on the presentation and progression of myeloma. As was previously mentioned in the HR-MM series, the cytogenetic changes of the myeloma cell form the basis for clonal evolution and are driving to plasma cell leukemia(PCL). The mutations enable the cell to dominate and win the protein wars. Morgan along with Walker f
This is a very helpful article for all of us who are constantly reading articles about health that make claims of ‘cure’ or what will ’cause cancer’. These analysis tips from Dr. Alicia White are quite good. She wrote them in 2009. Even five years latter, adhering to them will clearly result in less anxiety […]
There are several sites starting to appear across the internet that are patient friendly when it comes to explaining how immunotherapy is moving forward and rapidly bringing results for patients with all types of cancer. The field of oncoImmunology is taking off! Two new sites are ImmunID and Answer to Cancer. ImmunID is a […]
Once again at the European Hematology Association the IMF sponsored the discussion panel led by Dr. Brian Durie. The panel consisted of Palumbo, Landgren, Mikhael and Russell. The hour & a half video of the conference series can be found here. Below are a few highlights of the remarks made by the panel this year. […]
Recently, Gary Petersen and I co-authored a post about patient advocates and how they contribute to the myeloma community. It is just as important to become your own patient advocate. Cancer is one of those things that just drops into our lives unexpectedly and we are left in emotional chaos trying to determine what to […]
An FDA-NCI roundtable symposium on minimal residual disease (MRD) detection in multiple myeloma (MM) was held at the FDA in Silver Spring, Maryland in March of 2014. The goal of this meeting was twofold: (1) to examine the evidence on the clinical utility of MRD in MM as a bio surrogate marker for drug response; […]
“When a patient dies of cancer, hope can be replaced with questions. Could we have done something more? Should we have done something different? Would I make the same recommendations if I could counsel him (or her) all over again? Hope can transform into something altogether different, like the sun clouding over and its yellow […]
What irony. Have you heard of Roswell Park Cancer Center? “Dr. Roswell Park founded the Buffalo-based, world-renowned campus that bears his name in 1898.Now, more than 100 years later, his great-grandson is being treated there for Multiple Myeloma, a form of blood cancer. “It makes me particularly proud that my great […]
Do you take Pomalidomide? If so, be sure to follow your liver enzyme tests closely. The June issue of Lancet reports a case of hepatotoxicity in a myeloma patient on 2mg of pomalidomide therapy. The patient had previously experienced hepatoxicity while on 5mg of lenalidomide. Initially, the pomalidomide was 2mg three times daily and after […]
This is highly interesting news in terms of mortality rates seen with allogenic transplants. It seems that the more diverse a patients bowel microflora the greater their chance of survival following an allogenic transplants.
I read an article today where they quote Palumbo as saying myeloma ALWAYS has minimal residual disease thus continuous therapy is essential. Despite having attained a sCR I happen to agree with this perspective. Even though the disease may not be detectable with the best tools available how can we be confident it is gone? […]